Servier India partners with MedGenome, Strand Life Sciences to offer affordable cancer tests in India

Servier India, a subsidiary of the leading French pharmaceutical company Servier Group, has joined hands with genomic companies MedGenome and Strand Life Sciences to launch affordable biomarker tests for Acute Myeloid Leukaemia (AML), an aggressive blood cancer, and Cholangio carcinoma (CCA), a rare bile duct cancer.

The tests will be free in government hospitals and done at subsidised rates in private hospitals across the country, an official statement said.

Without subsidy, an AML test can cost anything between ₹20,000 and ₹50,000, while a CCA test can range from ₹70,000 to ₹3 lakh.

“At Servier, we believe that access to timely and precise diagnosis should never depend on where a patient lives or what they can afford. In cancers such as AML and CCA, early molecular testing may support timely and informed treatment decisions, positively impacting survival rates, yet far too many patients in India are still diagnosed too late. This initiative reflects our deep commitment to closing that gap — by working with leading partners like MedGenome and Strand Life Sciences to bring advanced biomarker testing closer to patients across India,” Aurelien Breton, Managing Director, Servier India, said.

The biomarker testing initiative is launched under the ‘Servier Care’ patient support programme, which offers comprehensive support to eligible patients, including financial assistance, free drug support, and subsidised diagnostics, ensuring holistic care throughout the treatment journey, where legally permissible.

Good-quality molecular testing remains concentrated in a small subset of the Indian population, primarily in urban centres. The initiative is expected to address that access problem.

“Precision oncology begins with precision diagnosis. Identifying key genetic mutations is essential in guiding treatment decisions for both AML and Cholangiocarcinoma, yet access to such molecular testing remains limited for many patients in India. Through this initiative, we aim to integrate advanced biomarker testing into routine oncology practice, enabling physicians to make informed, evidence-based treatment choices and ultimately improving patient outcomes,” Pratima Tripathi, Commercial Director – Oncology, Servier India, said.

“This initiative is about strengthening the last-mile coordination between labs, clinicians, and patient pathways — where most delays occur. Our role is to ensure these connections translate into timely action for doctors and patients,” Aliasgar Patanwala, Market Access Lead, Servier India, said.